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model. Subgroup and sensitivity analysis was also performed. RESULTS: Seven RCTs 
including 2110 HP positive patients were included in final analysis. Significant het-
erogeneity was observed for effectiveness (Cochran Q, P - < 0.012, I2 > 50%) and ADRs 
(Cochran Q, P- < 0.095, I2 > 50%). No significant publication bias was observed. TT was 
more effective (RR 0.69 (95% CI, 0.63-0.76)) than DT. TT was also well tolerated (RR, 
0.80 (95% CI, 0.41-1.54)) in comparison to DT. Results were not sensitive to various 
subgroup and sensitivity analysis. CONCLUSIONS: TT is found to be more effective 
and safe in comparison to DT for eradication of Helicobacter pylori.
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OBJECTIVES: The overproduction of free radicals is considered as a significant cause 
hepatotoxicity of doxorubicin, overshadowing its, otherwise, highly potent anti-
neoplastic effectiveness. of its side effects. The aim of our study was to evaluate the 
potential hepatoprotective properties of ursodeoxycholic acid (UDCA), its influence 
on lipid peroxidation (LPO) and expression of glutathione-dependent antioxida-
tive enzymes in the livers of rats treated with DOX. METHODS: Twenty four male 
Wistar rats were divided in four groups. Animals were administered either with 
vehicle (saline i.p. (K1) or saline i.p. with propylene glycol p.o. (K2)), DOX (3 mg/kg 
i.p. every other day for total 3 doses) or combined UDCA 25 mg/kg p.o. every other 
day for total 3 doses, starting one day before administering DOX. On the day 28 
animals were euthanized and the livers were immediately harvested in order to 
determine the expression of selected parameters of oxidative stress. RESULTS: In 
the livers of animals administered with DOX, LPO was increased compared to both 
control groups, whereas in DOX+UDCA group the intensity of LPO was decreased, 
closely to control values. Treatment with DOX significantly increased the specific 
activities of glutathione peroxidase (GPx) compared to control groups (p< 0.01 vs.K1 
and K2). Combined treatment with DOX+UDCA decreased GPx activity. Similarly, 
the activity of glutathione reductase was highest in group treated with DOX and 
lower in group treated with DOX+UDCA. Specific activity of glutathione-S-tran-
ferase was significantly increased in DOX-treated group compared to control groups 
(p< 0.05), and decreased in DOX+UDCA group, however without statistical signifi-
cance. CONCLUSIONS: According to its ability to decrease the LPO and modulate the 
activity of glutathione-dependent antioxidative system, UDCA represents an agent 
with potentially hepatoprotective properties against oxidative liver damage induced 
by high doses of DOX. Acknowledgment: Supported by the Ministry of Education, 
Science and Technological Development, Republic of Serbia, grant No.III41012.
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lIne helIcobAcTer PylorI (h. PylorI) erAdIcATIon: A neTwork meTA-
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OBJECTIVES: To determine whether the hybrid therapy (HBD), 14-day-sequential 
therapy (SEQ), and 14-day-concomitant therapy (QAD) result in superiority in terms 
of H. pylori eradication. METHODS: Randomized controlled trials comparing HBD, 
SEQ, and QAD regimens were extracted from a search of PubMed, EMBASE, and 
Cochrane Central Register of Controlled Trials between 1982 and 2014. Dichotomous 
data were pooled to obtained the odds ratio (OR) with 95% confidence intervals 
(CIs). Multivariate random-effects meta-regression was used to estimate the pooled 
effects. The primary outcome was eradication of H. pylori. The secondary outcome 
was overall side effects rate. RESULTS: Six studies were identified. Two compared 
HBD to SEQ, two compared HBD to QAD, and two compared SEQ to QAD. No trial 
compared all three regimens. In intention-to-treat (ITT) analysis, no significant 
superiority was observed among the three regimens in terms of eradication rate 
[HBD compared to SEQ (OR= 0.46, 95 CI: 0.15-1.37), HBD compared to QAD (OR= 
0.96, 95 CI: 0.34-2.70) and SEQ compared to QAD (OR= 2.10, 95 CI 0.67- 6.54)]. By 
ranking probability, HBD had a 49.5% chance of being the most likely regimen to 
achieve eradication, followed by QAD (46.3%). For the side effects, patients taking 
HBD had a significantly higher rate compared to those taking QAD (OR= 5.94, 95 
CI 1.74~20.30). No significant difference was observed when compared QAD to SEQ 
(OR= 0.52, 95 CI: 0.23-1.20), and HBD to SEQ (OR= 0.75, 95 CI: 0.32-1.76). By rank-
ing probability QAD had a 75% chance of being the regimen with the lowest side 
effect rate. CONCLUSIONS: No regimen demonstrated superiority in eradication. 
Considering both eradication rate and side effect rate, QAD should be considered for 
use as first-line therapy in clinical situations with concern for patient adherence.
PGI7
meTA-AnAlysIs of ulTrAsonIc scAlPel versus elecTrocAuTery In 
lAPAroscoPIc cholecysTecTomy In chInA
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OBJECTIVES: To evaluate the role of Ultrasonic scalpel versus electrocautery in 
laparoscopic cholecystectomy (LC) so as to understand how to achieve dissection 
and closure of cystic artery and duct in a safe and efficient approach. METHODS: 
Comparative studies with the subjects of Chinese population were searched till Dec 
2014 in PubMed, EMBASE, Cochrane Library, Chinese Biomedical Database, China 
Academic Journals Full-Text Database, Chinese Scientific Journals Database, and 
China Online Journals. The quality of included studies was evaluated by Handbook 
5.0.0. Cochrane Collaboration’s RevMan 5.0. was used to conduct meta-analysis 
with random effects model. RESULTS: A total of 8 comparative studies (5 RCT and 
3 retrospective comparative studies) were included with 1337 in ultrasonic scalpel 
group and 867 in electrocautery group. In laparoscopic cholecystectomy, compared 
with electrocautery, ultrasonic scalpel shows a statistically significant reduction in 
operation time (weighted mean difference [WMD], -9.38 minutes; 95% confidence 
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OBJECTIVES: Several meta-analyses comparing ciclosporin with immediate-release 
(IR) tacrolimus have been conducted. Only recently have sufficient data become 
available for evidence synthesis including prolonged-release (PR) tacrolimus. In the 
present study, a network meta-analysis (NMA) was conducted to compare the effi-
cacy of ciclosporin, IR and PR tacrolimus in liver transplant recipients. METHODS: 
Systematic literature review of PubMed, EMBASE and the Cochrane Library identified 
randomized controlled trials and large-scale observational studies (≥ 500 patients) 
published since January 2000 comparing IR tacrolimus with PR tacrolimus or ciclo-
sporin following primary liver transplant. A Bayesian NMA was conducted to evalu-
ate likelihood of death, graft loss, and acute rejection (AR) at 12 months. Outcomes 
were adjusted for recipient gender and age, hepatitis C (HCV) status, hepatocellular 
carcinoma, mycophenolate mofetil, azathioprine, and steroid use. RESULTS: Head-
to-head study results were available for ciclosporin versus IR tacrolimus (n= 14) and 
PR tacrolimus versus IR tacrolimus (n= 2). Relative to ciclosporin, IR and PR tacrolimus 
were associated with reduced likelihood of death within 12 months of transplant 
(median odds ratios [OR] of 0.78 and 0.60, respectively). Mortality outcomes were 
superior with PR versus IR tacrolimus (median OR of 0.76). AR was less common with 
IR tacrolimus compared with ciclosporin (median OR of 0.69), whereas limited data 
for PR tacrolimus was evidenced by large credible intervals. There were no significant 
differences with respect to graft loss. Sensitivity analyses indicated that results were 
robust to assumptions and changes in confounders. Confounder analysis found that 
patient age was associated with death, whereas HCV status was associated with AR 
and graft loss. CONCLUSIONS: Patient and treatment factors beyond immunosup-
pressive treatment influence outcomes. Results of this confounder-controlled analysis 
provide further evidence that tacrolimus has substantial benefits over ciclosporin 
in liver transplant recipients. Compared with IR tacrolimus, data indicate that PR 
tacrolimus is superior with respect to patient survival.
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OBJECTIVES: Several meta-analyses comparing ciclosporin with tacrolimus have 
been conducted since the 1994 publication of the tacrolimus registration trials, 
but most captured data from randomized controlled trials (RCTs) predate recent 
improvements in waiting list prioritization, induction protocols and concomitant 
medications. The present study comprised a systematic review, meta-analysis 
and indirect treatment comparison of ciclosporin, immediate-release (IR) and 
prolonged-release (PR) tacrolimus in liver transplant recipients using studies pub-
lished since January 2000. METHODS: Searches of PubMed, the Cochrane Library 
and EMBASE identified RCTs comparing IR tacrolimus with PR tacrolimus or ciclo-
sporin as the immunosuppressant in primary liver transplant recipients, published 
between January 2000 and August 2014. A random effects meta-analysis was con-
ducted to evaluate the relative risk of death, graft loss, acute rejection (AR), new-
onset diabetes after transplantation (NODAT) and hypertension with IR tacrolimus 
relative to ciclosporin at 12 months. An indirect comparison was then conducted 
between PR tacrolimus and ciclosporin. RESULTS: The literature search identified 
12 RCTs comparing ciclosporin with IR tacrolimus and one RCT comparing IR with 
PR tacrolimus. Relative to ciclosporin, IR and PR tacrolimus were both associated 
with significantly improved outcomes in terms of patient survival (risk ratios [RR] 
of 1.27; 95% confidence interval [95%CI] 1.03–1.57 and 1.27; 95%CI 1.02–1.58, respec-
tively). IR tacrolimus was superior to ciclosporin in terms of hypertension (RR 1.26; 
95%CI 1.12–1.42). There were no significant differences between ciclosporin and IR 
tacrolimus in terms of graft loss, AR or NODAT. CONCLUSIONS: Meta-analysis of 
RCTs published since 2000 showed IR and PR tacrolimus to be superior to ciclosporin 
in terms of patient survival and hypertension, while no significant differences were 
identified in terms of graft loss, AR or NODAT. These findings provide further evi-
dence supporting the use of tacrolimus as the cornerstone of immunosuppressive 
therapy in liver transplant recipients.
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An evIdence-bAsed meTA-AnAlysIs of rAndomIzed clInIcAl TrIAls
Dasari A., Gudala K., Bansal D.
National Institute of Pharmaceutical Education and Research, Mohali, India
OBJECTIVES: Helicobacter pylori (HP) is prime cause of the upper gastrointestinal 
(UGI) diseases, including certain cancers. The standard triple therapy (TT) (one pro-
ton pump inhibitors (PPI) and two antibiotics) is available for the eradication of H. 
pylori but due to the increased adverse drug reactions (ADRs), poor compliance, and 
growing antibiotic resistant, simple dual therapy (DT) (one PPI and one antibiotic) 
was introduced. But there is a conflict regarding the use of dual vs TT. Present meta-
analysis is aimed at exploring effectiveness of dual versus TT for eradication of 
HP. METHODS: Randomized clinical trials (RCTs) assessing effectiveness of DT vs TT 
in confirmed HP positive cases with minimum of 4 week post-treatment follow-up 
results were included. Literature search was done using appropriate MeSH terms. 
Full text articles published in English having complete data were included. Effect 
estimate was presented as risk ratio (Rr). Assessment of heterogeneity was done 
using Cochran Q and I2 tests. We pooled effectiveness and ADRs using random effect 
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and outcome of both surgical disciplines and the impact of numerous other fac-
tors. METHODS: Data were extracted from a major public health insurance claims 
database (~ 8 million clients) during a 3-year period (2010-2012). Patients aged 4-17 
years with appendectomy were included. Logistic regression analysis for risk of 
a surgical complication within the first 180-postoperative days was performed. 
Complications were defined by ICD and OPS codes. RESULTS: 8,110 patients were 
analyzed (PedSurg: n= 1,937; GenSurg: n= 6,173). Laparoscopic appendectomy was 
performed significantly more frequently by GenSurg compared to PedSurg (79% vs. 
61%). The complication rate during initial stay and the readmission rate for surgical 
complications were significantly higher in patients treated by PedSurg compared to 
those operated on by GenSurg (2.9% vs. 1.7% and 3.4% vs. 2.2% respectively, p< 0.01). 
Logistic regression analysis revealed no differences between the two surgical spe-
cialities for the risk of surgical complications during the initial hospital stay and 
no differences for the risk of readmission for a surgical complication in younger 
patients (4-11 years). In contrast, the risk of readmission for surgical complications 
in adolescents (12-17 years) was significantly higher if the patient was operated on 
by PedSurg (p< 0.01). The results showed that patients treated with laparoscopy had 
a significantly lower risk for developing surgical complications within the first 180 
postoperative days than patients who underwent an open surgery (OR: 0.73, p< 0.1). 
No differences were found for the variables geographical region and working day vs. 
weekendsurgery. CONCLUSIONS: With overall low complication and readmission 
rates after appendectomy this study revealed an excellent quality of care for appen-
dicitis in Germany. However, the increased risk of readmission for surgical compli-
cations in adolescent patients operated by PedSurg deserves future investigation.
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OBJECTIVES: A high prevalence of chronic kidney disease (CKD) in hepatitis C virus 
(HCV)-infected patients has been reported in Taiwan. By contrast, several studies 
in the United States (US) have not found an increased prevalence of CKD, suggest-
ing a possible geographic variation. We systematically reviewed the literature to 
determine the risk of developing of CKD in HCV-infected individuals. METHODS: 
MEDLINE and PUBMED were searched to identify observational studies that had 
reported an association between HCV and CKD or end-stage renal disease (ESRD) 
through 2014. Quantitative estimates (hazard ratio (HR) or odds ratio (OR)) and the 
95% confidence intervals (CI) were extracted from each study. Studies were system-
atically reviewed in accordance with PRISMA guidelines, and a random-effects meta-
analysis was performed. RESULTS: Eleven studies evaluating the risk of developing 
CKD/ESRD in HCV-infected individuals (n= 265714) compared to uninfected controls 
(n= 1674104) were identified- 7 cohort studies and 4 cross-sectional studies. The 
average years of follow-up ranged from 2.1 to 7.4 years. Five studies were from the 
US and 6 were from Taiwan. The pooled HR of CKD/ESRD in HCV+ individuals from 
the cohort studies was significant at 1.36 [95%CI:1.13-1.58] whereas the pooled OR 
from the cross-sectional studies was not- 1.16 [95%CI:0.92-1.40]. The overall pooled 
risk ratio from the 11 studies indicated that HCV+ individuals had a 30% greater 
risk of developing CKD/ESRD compared to uninfected individuals: risk ratio 1.29 
[95%CI:1.13-1.45]. Country-stratified analysis yielded a significantly increased risk 
between HCV and CKD in the Taiwanese subgroup (risk ratio= 1.24 [95%CI:1.05-1.48]) 
but not among the US subgroup (risk ratio= 1.23 [95%CI:0.92-1.54]). Egger regression 
revealed no evidence of publication bias. CONCLUSIONS: HCV infection is associ-
ated with a greater risk of developing CKD/ESRD compared to uninfected controls. 
This risk appears to be geographically linked with patients in Taiwan at higher risk 
for HCV related CKD/ESRD than those in the US.
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OBJECTIVES: To quantify liver transplant risk and mean total costs in treated versus 
untreated patients diagnosed with hepatitis C virus (HCV). METHODS: The sample 
included individuals with commercial or Medicare Advantage insurance, aged 19-89, 
with ≥ 1 HCV diagnosis or HCV treatment prescription claim between 1/1/2008 and 
6/30/2013, excluding those diagnosed with hepatitis B. Patients were observed during 
their full post-index enrollment following date of transplant or first HCV diagnosis or 
prescription. Cox proportional-hazard regression approximated adjusted relative risk 
(aRR) of transplant in treated versus untreated individuals, controlling for age, gender, 
geographic location, Deyo-Charlson Comorbidity Index, RxRisk-V Score, and pre-index 
medical and pharmacy costs. Results were also generated by treatment adherence 
level based on proportion of days covered (≥ 80%, 50-79%, < 50%). Mean total costs 
(plan- and patient-paid) were assessed over the observation period using generalized 
linear models with log link and gamma distribution. RESULTS: 93.7% (40,338/43,046) 
of the sample had no evidence of HCV treatment. Incidence of liver transplant was 
0.79% in untreated and 1.77% in treated individuals. There was no evidence that HCV 
treatment was associated with lower risk of transplant (aRR= 1.01, 95% confidence 
interval [CI] 0.80-1.50). Transplant risk in treated individuals did not vary by adherence 
(50-79% aRR= 0.86 [95% CI 0.19-2.72]; < 50% aRR= 1.73 [95% CI 0.73-4.38]; reference group 
≥ 80%). Transplant recipients incurred significantly higher mean total costs compared 
to those without transplant ($154,250 vs. $38,128, p< 0.0001). Among transplant recipi-
ents, costs were higher for treated versus untreated patients ($237,949 vs $141,616, 
p< 0.0001). CONCLUSIONS: Despite adjusting for covariates, there was no evidence 
that HCV treatment reduced risk of liver transplant, suggesting that treated patients 
may be sicker and have unmeasured confounders. However, within the treated group, 
there was no change in risk of transplant by level of adherence, underscoring the need 
for further evidence on liver transplant outcomes.
interval [CI], (-14.89 to -3.89 minutes) (P = 0.0008); intraoperative blood loss (WMD, 
-12.41 mL; 95% CI, -18.20 to -6.62 mL) (P < 0.0001); length of hospital stay (weighted 
mean difference [WMD], -1.23 days; 95% CI, (-1.68 to -0.78 days) (P < 0.00001); and 
recovery time of intestine function (weighted mean difference [WMD], -2.96 days; 
95% CI, (-5.20 to -0.72 days) (P = 0.01). There were also significant differences in intra-
operative complication rate (OR= 0.23, 95% CI (0.06,0.87), P= 0.03) and in postoperative 
complication rate (OR= 0.11, 95% CI (0.02,0.62), P= 0.01). CONCLUSIONS: This meta-
analysis clearly demonstrates that compared with electrocautery, ultrasonic scalpel 
can statistically significant reduce operation time, intraoperative blood loss, length 
of hospital stay, recovery time of intestine function, intraoperative complication rate 
and postoperative complication rate in LC in Chines population. It evidences that in 
China, ultrasonic scalpel offers a wide range of clinically relevant advantages and all 
of these advantages have clear economic impacts in laparoscopic cholecystectomy.
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OBJECTIVES: To describe current clinical characteristics and healthcare utiliza-
tion of CHC patients treated with newer DAA-based regimens using claims-linked 
lab data from a large US health plan. METHODS: The Optum Research Database 
(ORD) with medical and pharmacy claims-linked lab data for commercially-
insured patients and Medicare Advantage beneficiaries was used. Patients with 
CHC ≥ 18 years treated with simeprevir (SMV) and/or sofosbuvir (SOF) regimens 
after Nov2013 and with 6-months baseline health plan enrollment were followed 
from treatment initiation until Jun2014. ORD contained 123.1M cumulative lives 
as of Jun2014. RESULTS: 1,844 CHC patients were treated with SOF+RBV (33%) SOF 
+PEG+RBV (32%), SMV+SOF (29%) and SMV+SOF+RBV (6%) (n= 51 were treated with 
other regimens and excluded from analysis). Less than half of patients had a cir-
rhosis diagnosis (37%). 24% had claims-based evidence of end-stage liver disease. 
Over half (65%) were male; 68% white and 14% black; mean age was 57.5 years 
(SD= 9.5). One-third (33%) were Medicare beneficiaries; 67% were commercially 
insured. Mean treatment duration for completed regimens (n= 339) was 10.7 weeks; 
over half of regimens had treatment durations of > 11 to ≤ 15 weeks (57%). Among 
patients with genotype results available (n= 597), 1a (51%) was most common, fol-
lowed by 1b (18%) and 2 (17%). Approximately one-third of patients with liver func-
tion test results (n= 658) had baseline advanced liver fibrosis (29% with APRI > 1.5; 
33% with FIB-4 > 3.25). Significant variations in treatment regimen were seen across 
liver disease severity subgroups, including those with advanced liver fibrosis most 
often being treated with SMV+SOF and SOF+RBV. Healthcare resource utilization 
and cost per SVR will be examined when post-treatment outcomes data are avail-
able. CONCLUSIONS: The analysis provides current CHC treatment patterns in a 
large US payer database, evidence of potential variation in newer DAA treatment 
utilization by clinical characteristics, and suggests a significantly higher proportion 
of patients receiving SMV+SOF±RBV had advanced liver fibrosis.
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OBJECTIVES: Infliximab is associated with fewer Crohn’s disease (CD)-associated 
hospitalizations in randomized efficacy trials. Testing the effectiveness of inflixi-
mab using administrative data is challenging because many clinical predictors (i.e., 
degree of inflammation) are not available in coded data. We aimed to examine the 
effectiveness of infliximab on CD-related hospitalizations adjusting for confound-
ers using high-dimensional data mining. METHODS: A sample of CD cases was 
identified by at least two encounters for International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) code 555 from all active duty U.S. 
military personnel with service between 2001 and 2012. CD is an exclusion crite-
rion for enlistment resulting in an incident cohort. Outpatient Current Procedural 
Terminology (CPT) codes were used to identify early infliximab use (within 6 months 
of diagnosis). The outcome of interest was hospitalization after 6 months of diag-
nosis. We applied an algorithm to select confounding risk factors with a minimum 
prevalence of 0.04%. Univariable predictors with p< 0.05 were eligible for the final 
multivariable selection model (inclusion threshold p< 0.01). RESULTS: During a 
median of 2.04 years of follow-up, 10% of the 990 eligible patients used infliximab 
within 6 months of diagnosis, 30% were hospitalized within the first 6 months of 
diagnosis and 9% were hospitalized after 6 months. Early infliximab use was associ-
ated with an increased odds of hospitalization > 6 months (OR 0.76; 95% CI 0.26 – 
2.21) after adjustment for 64 model-selected factors including number of encounters 
(OR 0.98), abdominal pain (OR 5.39) and CT scan (OR 5.76). CONCLUSIONS: In this 
incident cohort of CD, early use of infliximab was not associated with a statistically 
significant decreased in hospitalizations, although the direction of effect was similar 
to trial results. These findings indicate that high dimensional data mining adjust-
ment is an option for modeling medication-outcome relationships.
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OBJECTIVES: In Germany children with appendicitis are treated by pediatric sur-
geons (PedSurg) as well as general surgeons (GenSurg). We analyzed the treatment 
